This is a beta version of OpenPrescribing Hospitals for testing and feedback purposes. Data and functionality may be incomplete. Please contact us if you find any issues or have feedback.
This measure supports work to improve efficiency in hospitals.
The percentage of pertuzumab that is issued as the combined preparation, Phesgo®.
We divide the number of products containing trastuzumab and pertuzumab (Phesgo®) by the total number of products containing pertuzumab including Phesgo®. We then multiply that by 100 to obtain the % each month.
Trastuzumab and pertuzumab are used to treat breast cancer. If given separately, they are administered via two intravenous infusions which can take up to two and a half hours. This uses a lot of nursing time and most importantly the patients time. Phesgo® is a combination of trastuzumab and pertuzumab and is administered as a subcutaneous injection, in a fraction of the time. Phesgo® was made available in 2021 and was highlighted by NHSE as a medicines optimisation opportunity to improve equitable adoption of the most clinically and cost-effective medicines.
Trusts are only included in this measure if they have issued any products included in the denominator for this measure.
For this measure, 120/225 Trusts are included. A full list of Trusts included is available on the Submission History page.